Related Experiment Video
Updated: Jan 19, 2026
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
Published on: November 14, 2016
Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis
Valtteri Kaasinen1, Juho Joutsa1, Eero Rissanen1
1Department of Neurology, University of Turku, Turku, Finland; Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland.
Abstract:
Dopamine has a modulatory role in a number of autoimmune diseases, but there are no published cases of longitudinal dopaminergic imaging in multiple sclerosis (MS). Here we report a patient with primary progressive multiple sclerosis (PPMS) who was scanned twice with brain dopamine transporter single photon emission computed tomography (SPECT) with an interval of four years. The results showed a loss of tracer binding that corresponded to a 4-7 fold steeper decline than in normal ageing. The finding points to a relevant role of nigrostriatal dopaminergic degeneration in the pathological process of PPMS.
Related Concept Videos
08:11Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
11:35The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
09:41Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
28:15Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
08:18A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...